fda bans compounded semaglutide and tirzepatide moves to remove GLP-1 medications from 503B Bulks List FDA announces ban for compounded
Description
This blog isnt about convincing you to start a medication or telling you to stop one

Order online!
Here, the authors review the physiological roles of GLP-1, the potential renoprotective mechanisms of incretin-based therapies and the available renal outcome data from clinical trials.

Additionally, we highlight the gaps for further studies in clinical applications of GLP-1 RAs in aging-related diseases
